Geissoschizoline

BIOLOGICAL ACTIVITY		
Description	Geissoschizoline ((+)-Geissoschizoline) is a potent inhibitor of human AChE/BChE, with IC ₅₀ s of 20.40 μM and 10.21 μM, respectively. Geissoschizoline emerges as a possible multi-target prototype that can be very useful in studies of preventing neurodegeneration and restoring neurotransmission. Geissoschizoline aiso is a potent anti-inflammatory agent ^[1] .	
IC ₅₀ & Target	IC50: 20.40 μM (AChE), 10.21 μM (BChE) ^[1]	
In Vitro	Geissoschizoline(1 μM; 48 hours) significantly reduces production of TNF-α and NO in LPS-stimulated microglial cells ^[1] . Geissoschizoline(1, 10 and 30 μM; 24 hours) shows no cytotoxicity to LPS-stimulated microglial cells ^[1] MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]	
	Cell Line:	LPS-stimulated microglial cells (pre-incubated with various concentrations (0.1- 10 $\mu M)$ of geissoschizoline for 1 hour)
	Concentration:	1 μM
	Incubation Time:	48 hours
	Result:	Reduced neuroinflammation and increased neuroprotection, also restored synaptic transmission.
	Cell Cytotoxicity Assay ^[1]	
	Cell Line:	LPS-stimulated microglial cells
	Concentration:	1, 10 and 30 μM
	Incubation Time:	24 hours
	Result:	Did not affect cell viability.

REFERENCES

Product Data Sheet



[1]. Josélia A Lima, et al. Geissoschizoline, a promising alkaloid for Alzheimer's disease: Inhibition of human cholinesterases, anti-inflammatory effects and molecular docking. Bioorg Chem. 2020 Nov;104:104215.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA